52

T0901317

52 Publications Verification

Cat. No.: HY-10626

CAS No.: 293754-55-9

Purity: 99.93%

Target:

LXR FXR ROR Apoptosis

Research Areas:

Cardiovascular Disease Metabolic Disease Cancer

T0901317 is an orally active and highly selective LXR agonist with an EC₅₀ of 20 nM for LXRα . T0901317 activates FXR with an EC₅₀ of 5 μM . T0901317 is RORα and RORγ dual inverse agonist with K_i values of 132 nM and 51 nM, respectively . T0901317 induces apoptosis and inhibits the development of atherosclerosis in low-density lipoprotein (LDL) receptor-deficient mice .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

31

BMS-309403

31 Cited Publications

Cat. No.: HY-101903

CAS No.: 300657-03-8

Purity: 99.93%

Target:

FABP

Research Areas:

Cardiovascular Disease Metabolic Disease

BMS-309403 is a potent, orally active and selective adipocyte fatty acid binding protein (also known as FABP4, aP2) inhibitor with K_is of <2, 250, and 350 nM for FABP4, FABP3, and FABP5, respectively. BMS-309403 interacts with the fatty-acid-binding pocket within the interior of the protein and competitively inhibits the binding of endogenous fatty acids. BMS-309403 improves endothelial function in apolipoprotein E-deficient mice and in cultured human endothelial cells .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

31

BMS-309403 sodium

31 Cited Publications

Cat. No.: HY-101903A

CAS No.: 2802523-05-1

Purity: 99.93%

Target:

FABP

Research Areas:

Cardiovascular Disease Metabolic Disease

BMS-309403 sodium is a potent, orally active, and selective adipocyte fatty acid binding protein (also known as FABP4, aP2) inhibitor, with K_is of <2, 250, and 350 nM for FABP4, FABP3, and FABP5, respectively. BMS-309403 sodium interacts with the fatty-acid-binding pocket within the interior of the protein and competitively inhibits the binding of endogenous fatty acids. BMS-309403 sodium improves endothelial function in apolipoprotein E-deficient mice and in cultured human endothelial cells .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

21

CC-885

21 Cited Publications

Cat. No.: HY-101488

CAS No.: 1010100-07-8

Purity: 99.85%

Target:

Molecular Glues Ligands for E3 Ligase Eukaryotic Release Factor (eRF) Apoptosis

Research Areas:

Neurological Disease Cancer

CC-885, a cereblon (CRBN) modulator, acts as a molecular glue degrader targeting GSPT1 with a K_d of 350 nM. CC-885 binds to CRBN to alter the substrate specificity of the CRL4 E3 ligase, promoting the ubiquitination and proteasomal degradation of GSPT1, BNIP3L, PLK1, CDK4, IKZF1/3, GSPT2, WIZ, CHD7, GOLM1, CK1α and ETS1. CC-885 induces apoptosis, cell cycle arrest, transcriptional downregulation and antiproliferation in cancer cells. CC-885 is applicable to research related to relapsed/refractory acute myeloid leukemia, MYC-driven tumors, metastatic castration-resistant prostate cancer, multiple myeloma, hepatocellular carcinoma, glioblastoma, VHL-deficient clear cell renal cell carcinoma and non-small cell lung cancer .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

11

Necrostatin 2

11 Cited Publications

Cat. No.: HY-14622

CAS No.: 852391-19-6

Purity: 99.92%

Target:

RIP kinase

Research Areas:

Cancer

Necrostatin 2 is a potent necroptosis inhibitor. EC₅₀ for inhibition of necroptosis in FADD-deficient Jurkat T cells treated with TNF-α is 0.05 μM. Necrostatin 2 is also a RIPK1 inhibitor.

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

5

Fluzoparib

5 Cited Publications

Cat. No.: HY-114778

CAS No.: 1358715-18-0

Purity: 99.96%

Synonyms: SHR3162; Fuzuloparib

Target:

PARP

Research Areas:

Cancer

Fluzoparib (SHR3162) is a potent and orally active PARP1 inhibitor (IC₅₀=1.46±0.72 nM, a cell-free enzymatic assay) with superior antitumor activity. Fluzoparib selectively inhibits the proliferation of homologous recombination repair (HR)-deficient cells, and sensitizes both HR-deficient and HR-proficient cells to cytotoxic agents. Fluzoparib exhibits good pharmacokinetic properties in vivo and can be used for BRCA1/2-mutant relapsed ovarian cancer research .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

4

Dihomo-γ-linolenic acid

4 Cited Publications

Cat. No.: HY-A0143

CAS No.: 1783-84-2

Synonyms: DGLA; all-cis-8,11,14-Eicosatrienoic acid

Category:

Cardiovascular Disease Ketones, Aldehydes, Acids Disease markers Endocrine diseases Endogenous metabolite Disease Research Fields Inflammation/Immunology

Target:

Endogenous Metabolite

Dihomo-γ-linolenic acid (DGLA) is a 20-carbon ω-6 fatty acid, with anti-inflammatory and anti-proliferative activities. Dihomo-γ-linolenic acid attenuates atherosclerosis in the apolipoprotein E deficient mouse model system .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

4

D-I03

4 Cited Publications

Cat. No.: HY-124691

CAS No.: 688342-78-1

Purity: 99.70%

Target:

DNA/RNA Synthesis

Research Areas:

Cancer

D-I03 is a selective RAD52 inhibitor with a K_d of 25.8 μM. D-I03 specifically inhibits RAD52-dependent single-strand annealing (SSA) and D-loop formation with IC₅₀s of 5 μM and 8 μM, respectively. D-I03 suppresses growth of BRCA1- and BRCA2-deficient cells and inhibits formation of damage-induced RAD52 foci, but does not effect on RAD51 foci induced by Cisplatin .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

4

Dihomo-γ-linolenic acid sodium

4 Cited Publications

Cat. No.: HY-A0143A

CAS No.: 65881-87-0

Synonyms: DGLA sodium; all-cis-8,11,14-Eicosatrienoic acid sodium

Category:

Microorganisms Ketones, Aldehydes, Acids

Target:

Endogenous Metabolite

Dihomo-γ-linolenic acid sodium (DGLA sodium) is a 20-carbon ω-6 fatty acid, with anti-inflammatory and anti-proliferative activities. Dihomo-γ-linolenic acid sodium attenuates atherosclerosis in the apolipoprotein E deficient mouse model system .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

4

Mitapivat

4 Cited Publications

Cat. No.: HY-12689

CAS No.: 1260075-17-9

Purity: 99.84%

Synonyms: AG-348

Target:

Pyruvate Kinase

Research Areas:

Metabolic Disease

Mitapivat (AG-348) is an orally active pyruvate kinase allosteric activator. Mitapivat increases enzymatic activity, protein stability, and ATP levels over a broad range of PKLR genotypes, shows the potential to restore the activity of PK (pyruvate kinase)-deficient glycolytic pathways. Mitapivat can be used in study of PK deficiency .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

3

FHD-609

3 Cited Publications

Cat. No.: HY-153367

CAS No.: 2676211-64-4

Purity: 99.15%

Target:

PROTACs Epigenetic Reader Domain c-Myc Hemoglobin

Research Areas:

Endocrinology Cancer

FHD-609 is a BRD9 PROTAC degrader. FHD-609 induces BRD9 degradation, downregulates primary transcripts of HBG/HBD, Myc expression and proliferation gene sets, reduces the levels of synovial sarcoma tumor proliferation markers, and inhibits tumor growth. FHD-609 can be used in research related to advanced synovial sarcoma, SMARCB1-deficient tumors and adrenocortical carcinoma .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

3

CFT8634

3 Cited Publications

Cat. No.: HY-145925B

CAS No.: 2704617-96-7

Purity: 98.10%

Target:

PROTACs Epigenetic Reader Domain

Research Areas:

Cancer

CFT8634 is an orally active BRD9 PROTAC degrader with a DC₅₀ of 0.003 μM (HEK293T.166). CFT8634 recruits the CRBN E3 ubiquitin ligase to form a ternary complex, triggering CRBN-catalyzed BRD9 polyubiquitination and 26S proteasome-mediated degradation. CFT8634 induces sustained tumor regression and inhibits tumor growth in mouse models. CFT8634 can be used in research related to synovial sarcoma, SMARCB-1-deficient cancers, acute myeloid leukemia, malignant rhabdoid tumors, and multiple myeloma .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

3

Irsogladine

3 Cited Publications

Cat. No.: HY-B0327

CAS No.: 57381-26-7

Synonyms: Dicloguamine

Target:

Phosphodiesterase (PDE) NF-κB AP-1 TRP Channel Interleukin Related

Research Areas:

Inflammation/Immunology Cancer

Irsogladine (Dicloguamine) is an orally active gastric mucosal protective agent. Irsogladine inhibits breast cancer recurrence and lung metastasis in nude mice . Irsogladine inhibits the transcriptional activities of NF-κB and AP-1, suppresses the activities of PDE and PDE4 to elevate intracellular cAMP levels, and activates TRPV1 and K_ATP channels. Irsogladine enhances iNOS expression, NO production, and the activation of cAMP-responsive elements. Irsogladine inhibits the development and progression of intestinal polyps in Apc-mutant mice. Irsogladine alleviates oxidative stress, increases gastric mucosal blood flow, and stimulates the production of endogenous prostaglandins. Irsogladine promotes insulin secretion in MIN6 cells. Irsogladine inhibits tumor angiogenesis, cancer cell proliferation, and the production of proinflammatory cytokines. Irsogladine exerts protective effects on astrocytes in ethanol/hydrochloric acid-induced gastric ulcers in mice. Irsogladine prevents colitis in IL-10 gene-deficient mice by reducing the production of IL-12 and IL-23. Irsogladine upregulates gap junction intercellular communication in pancreatic cancer cells via the PKA pathway. Irsogladine is applicable to research related to breast cancer, intestinal polyposis, gastric ulcer, spontaneous colitis, glioma, liver cancer, and pancreatic cancer ^[5][6] .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

2

STF-62247

2 Cited Publications

Cat. No.: HY-100746

CAS No.: 315702-99-9

Purity: 98.69%

Target:

Autophagy

Research Areas:

Cancer

STF-62247 is an autophagy inducer that selectively cytotoxic to VHL-deficient renal cell carcinoma (IC₅₀ of 0.625 μM and 16 μM in RCC4 and RCC4/VHL cells, respectively) .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

2

2'-O-Methyladenosine (Standard)

2 Cited Publications

Cat. No.: HY-W011552R

CAS No.: 2140-79-6

Category:

Natural Products Endogenous metabolite

Target:

Reference Standards Endogenous Metabolite

2'-O-Methyladenosine (Standard) is the analytical standard of 2'-O-Methyladenosine. This product is intended for research and analytical applications. 2'-O-Methyladenosine, a methylated adenine residue is found in urine of normals as well as in urine of adenosine deaminase (ADA) deficient patients. 2'-O-Methyladenosine exhibits unique hypotensive activities .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

1

Dihydrouracil

1 Cited Publications

Cat. No.: HY-W012926

CAS No.: 504-07-4

Synonyms: 5,6-Dihydrouracil

Category:

Natural Products Microorganisms Disease markers Metabolic Disease Endocrine diseases Endogenous metabolite Disease Research Fields

Target:

Endogenous Metabolite

Dihydrouracil (5,6-Dihydrouracil), a metabolite of Uracil, can be used as a marker for identification of dihydropyrimidine dehydrogenase (DPD)-deficient .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

1

M47

1 Cited Publications

Cat. No.: HY-148764

CAS No.: 890808-56-7

Purity: 99.90%

Target:

Cryptochrome Molecular Glues Apoptosis

Research Areas:

Cancer

M47 is a molecular glue that selectively destabilizes Cryptochrome 1 (CRY1) and increases degradation of the CRY1 in the nucleus. M47 enhances apoptosis in Ras-transformed P53-deficient mouse skin fibroblast lines and enhances life span in p53 knockout mice. M47 can be used in research of cancer .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

1

UNC10142

1 Cited Publications

Cat. No.: HY-159989

CAS No.: 3118919-69-7

Target:

Epigenetic Reader Domain

Research Areas:

Cancer

UNC10142 is a selective CHD1 antagonist with an IC₅₀ of 1.7 μM and a K_d of 4.3 μM. UNC10142 exhibits anticancer activity against PTEN-deficient prostate cancer but shows no effect on PTEN-intact prostate cancer. UNC10142 can be used in studies related to PTEN-deficient prostate cancer .

Compare

loading...